Table 3.

Baseline characteristics of 71 IMN patients for detecting circulating anti-PLA2R antibody and PLA2R expression in different genotypes

CharacteristicPLA2R Low Risk/HLA Low RiskPLA2R Low Risk/HLA High RiskPLA2R High Risk/HLA Low RiskPLA2R High Risk/HLA High RiskP Value
Patients (n)1952126
Age (yr)44±1154±752±1448±90.12
Sex (men/women)7/123/29/128/180.62
Systolic BP (mmHg)126±23129±11127±14127±180.99
Diastolic BP (mmHg)79±1280±1380±981±140.97
Proteinuria (g/24 h)4.04 (0.58, 13.15)11.07 (2.81, 19.33)4.56 (0.69, 16.49)4.09 (0.68, 8.12)0.85
Serum albumin (g/L)28.07±9.0525.22±8.2025.47±5.3326.27±6.740.70
Serum creatinine (μmol/L)76.46±26.9987.04±28.1366.86±19.0266.82±18.830.16
Total cholesterol (mmol/L)8.65±4.988.74±2.817.93±2.367.12±2.080.49
Total triglycerides (mmol/L)3.34±2.782.52±1.063.08±1.622.20±1.030.23
Estimated GFR (ml/min per 1.73 m2)104.32±37.0889.10±35.95118.81±39.30115.94±26.750.25
Pathology stage (I/II,III)16/35/010/1110/16<0.001
No immunosuppressive treatment (%)14 (74)2 (40)15 (71)19 (73)0.86
Anti-PLA2R (%)0 (0)1 (20)16 (76)19 (73)<0.001
Anti-PLA2R in patients without immunosuppressive therapy (%)0 (0, 0/14)0 (0, 0/2)11 (73, 11/15)17 (89, 17/19)<0.001
PLA2R staining in glomeruli (%)0/19 (0)2/5 (40)16/21 (76)18/24 (75)<0.001
  • Data are presented as mean ± SEM or median (interquartile range) unless otherwise indicated. PLA2R1 low risk, individuals with CC in rs35771982, CC in rs3749117, GG in rs4664308 within PLA2R1; PLA2R1 high risk, individuals with GG in rs35771982, TT in rs3749117, AA in rs4664308 within PLA2R1; HLA-DQA1 low risk, individuals with GG in rs2187668 within HLA-DQA1; HLA-DQA1 high risk, individuals with AA or GA in rs2187668 within HLA-DQA1.